Multiple Myeloma

<p>Multiple myeloma is the second most prevalent hematological malignancy with over 55000 new cases diagnosed each year. This exciting new text edited by lauded authorities on the topic stands as the only available reference to assemble review and synthesizes the latest studies on translational therapies and clearly explains the impact of molecular pathogenesis biology and prognostic factors on the diagnosis prognosis and individualization of treatment and the development of novel therapeutic options for patients with myeloma.<br><br>Moving from the bench to the bedside to the forefront of therapeutic development this source:</p><ul> <li>helps clinicians and researchers effectively deploy therapeutic strategies into clinical practice</li> <li>reflects trends in the use of agents which target both the tumor cell and its bone marrow microenvironment to overcome resistance to conventional therapies</li> <li>considers the critical role of the bone marrow microenvironment in the regulation of growth survival and homing of multiple myeloma</li> <li>discusses novel therapies in phase I and phase II trials focusing specifically on therapeutic options for patients with newly diagnosed or relapsed/refractory multiple myeloma</li> <li>addresses novel therapies for other plasma cell disorders and provides the framework for the design of next generation agents and combination therapies</li> <li>covers the entire scope of translational work in multiple myeloma from advances in molecular pathogenesis to prognostic factors immunotherapy and new options for newly diagnosed and relapsed multiple myeloma patients</li> </ul>